VNDA · Vanda Pharmaceuticals Inc.
$5.22
+0.19 (+3.78%)
At close · Aug 14
Market Cap
$315.62M
Shares
60.46M
Vanda Pharmaceuticals Inc. Earnings Call Transcripts
Every quarterly earnings call for Vanda Pharmaceuticals Inc. (VNDA) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼6.8%
$65.32M
$3.27M
'22 Q3
22-11-02
▼5.2%
$64.48M
$6.86M
'22 Q4
23-02-08
▲3.8%
$62.50M
$3.25M
'23 Q1
23-05-03
▼28.5%
$46.06M
$1.52M
'23 Q2
23-07-27
▼40.6%
$38.81M
$137,000
'23 Q3
23-11-08
▼29.8%
$45.27M
−$2.40M
'23 Q4
24-02-07
▼24.1%
$47.46M
−$4.15M
'24 Q1
24-05-08
▲9.6%
$50.47M
−$4.52M
'24 Q2
24-07-31
▲22.8%
$47.65M
−$5.32M
'24 Q3
24-11-06
▲17.5%
$53.19M
−$4.91M
'24 Q4
25-02-13
▲5.4%
$50.04M
−$29.49M
'25 Q1
25-05-07
▲4.2%
$52.59M
−$27.21M
'25 Q2
25-07-31
▲18.1%
$56.26M
−$22.59M
'25 Q3
25-10-29
▲7.6%
$57.22M
−$141.19M
'25 Q4
26-02-11
▲3.4%
$51.72M
−$48.57M
'26 Q1
26-05-06
LATEST
▼3.9%
$50.53M
−$62.51M
'26 Q2
26-08-05
Earnings call
FY26 · Q2
2026-08-05
Q2 2026 Vanda Pharmaceuticals Inc. Earnings Conference Call 04:30 PM EDT
Positive tone
Pipeline catalysts and readouts
GLP-1 adjunctive indication
Fanapt commercial growth
Revenue
$50.53M
▼ 3.9% YoY Diluted EPS
$-1.04
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-05-19
H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ 02:00 PM EDT
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-06
Vanda Pharmaceuticals Inc. Q1 FY2026 Earnings Call
Confident tone
Fanapt commercial momentum
Dysanti (milsoperidone) approval and pipeline
Nirius launch and DTC platform
Revenue
$51.72M
▲ 3.4% YoY Diluted EPS
$-0.82
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-11
Vanda Pharmaceuticals Inc. Q4 FY2025 Earnings Call
Confident tone
Fanapt commercial growth
Tradipitant (Nereus) motion sickness approval and launch
2026 revenue guidance and pipeline catalysts
Revenue
$57.22M*
▲ 7.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-29
Vanda Pharmaceuticals Inc. Q3 FY2025 Earnings Call
Confident tone
Fanapt commercial growth and bipolar launch
PONVORY commercial buildout
HETLIOZ market share despite generics
Revenue
$56.26M
▲ 18.1% YoY Diluted EPS
$-0.38
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-31
Vanda Pharmaceuticals Inc. Q2 FY2025 Earnings Call
Confident tone
Fanapt growth and sales force expansion
Bysanti NDA and pipeline catalyst
PONVORY commercialization
Revenue
$52.59M
▲ 4.2% YoY Diluted EPS
$-0.46
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-07
Vanda Pharmaceuticals Inc. Q1 FY2025 Earnings Call
Confident tone
Long-acting injectable development
Fanapt commercial growth
Pipeline and regulatory milestones
Revenue
$50.04M
▲ 5.4% YoY Diluted EPS
$-0.50
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-13
Vanda Pharmaceuticals Inc. Q4 FY2024 Earnings Call
Confident tone
Fanapt bipolar launch and growth
Vantrela / milsaperidone NDA
Ponvory MS launch and label expansion
Revenue
$53.19M*
▲ 17.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-06
Vanda Pharmaceuticals Inc. Q3 FY2024 Earnings Call
Positive tone
Fanapt bipolar I launch and sales force build-out
PONVORY multiple sclerosis commercialization
Milsaperidone pipeline development
Revenue
$47.65M
▲ 22.8% YoY Diluted EPS
$-0.09
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-07-31
Vanda Pharmaceuticals Inc. Q2 FY2024 Earnings Call
Positive tone
Fanapt bipolar I approval and commercial expansion
PONVORY acquisition and MS launch
HETLIOZ generic erosion
Revenue
$50.47M
▲ 9.6% YoY Diluted EPS
$-0.08
▼ 366.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Vanda Pharmaceuticals Inc. Q1 FY2024 Earnings Call
Positive tone
Fanapt bipolar I approval and lifecycle
PONVORY acquisition and commercial transition
HETLIOZ franchise and challenges
Revenue
$47.46M
▼ 24.1% YoY Diluted EPS
$-0.07
▼ 216.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-07
Vanda Pharmaceuticals Inc. Q4 FY2023 Earnings Call
Balanced tone
HETLIOZ insomnia sNDA and FDA dispute
Generic competition and revenue
Tradipitant gastroparesis NDA
Revenue
$45.27M*
▼ 29.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Vanda Pharmaceuticals Inc. Q3 FY2023 Earnings Call
Revenue
$38.81M
▼ 40.6% YoY Diluted EPS
$0.00
▼ 100% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-07-27
Vanda Pharmaceuticals Inc. Q2 FY2023 Earnings Call
Revenue
$46.06M
▼ 28.5% YoY Diluted EPS
$0.03
▼ 40% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-03
Vanda Pharmaceuticals Inc. Q1 FY2023 Earnings Call
Revenue
$62.50M
▲ 3.8% YoY Diluted EPS
$0.06
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-08
Vanda Pharmaceuticals Inc. Q4 FY2022 Earnings Call
Revenue
$64.48M*
▼ 5.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-02
Vanda Pharmaceuticals Inc. Q3 FY2022 Earnings Call
Revenue
$65.32M
▼ 6.8% YoY Diluted EPS
$0.06
▼ 57.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-03
Vanda Pharmaceuticals Inc. Q2 FY2022 Earnings Call
Revenue
$64.39M
▼ 5.2% YoY Diluted EPS
$0.05
▼ 70.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Vanda Pharmaceuticals Inc. Q1 FY2022 Earnings Call
Revenue
$60.19M
▼ 4% YoY Diluted EPS
$-0.11
▼ 173.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-23
Vanda Pharmaceuticals Inc. Q4 FY2021 Earnings Call
Revenue
$68.02M*
▲ 0.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-03
Vanda Pharmaceuticals Inc. Q3 FY2021 Earnings Call
Revenue
$70.09M
▲ 16.2% YoY Diluted EPS
$0.14
▲ 27.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-07-28
Vanda Pharmaceuticals Inc. Q2 FY2021 Earnings Call
Revenue
$67.90M
▲ 9.2% YoY Diluted EPS
$0.17
▲ 6.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-05
Vanda Pharmaceuticals Inc. Q1 FY2021 Earnings Call
Revenue
$62.67M
▲ 8% YoY Diluted EPS
$0.15
▲ 1400% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-10
Vanda Pharmaceuticals Inc. Q4 FY2020 Earnings Call
Revenue
$67.65M
▲ 11% YoY Diluted EPS
$0.15
▲ 87.5% YoY Gross margin
90.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-10-28
Vanda Pharmaceuticals Inc. Q3 FY2020 Earnings Call
Revenue
$60.31M
▲ 1.4% YoY Diluted EPS
$0.11
▼ 94% YoY Gross margin
89.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-05
Vanda Pharmaceuticals Inc. Q2 FY2020 Earnings Call
Revenue
$62.21M
▲ 5.3% YoY Diluted EPS
$0.16
▼ 23.8% YoY Gross margin
90.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-06
Vanda Pharmaceuticals Inc. Q1 FY2020 Earnings Call
Revenue
$58.00M
▲ 21.6% YoY Diluted EPS
$0.01
Gross margin
90.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-25
Vanda Pharmaceuticals Inc. Q4 FY2019 Earnings Call
Revenue
$60.93M
▲ 14.9% YoY Diluted EPS
$0.08
▼ 57.9% YoY Gross margin
89.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–28 of 28 earnings calls
Key facts
CIK
1347178
CUSIP
921659108
13F (30d)
164 filings
160 filers
Visit website
Investor relations